Sign in
Taking people in United StatesPhase 1/2

Choosing donor blood by RH genes for sickle cell disease

Tests donor blood picked by RH genes in sickle cell disease.

Key facts

Who runs it
Children's Hospital of Philadelphia
Where
Philadelphia, United StatesSee the site
Trial code
Registry title
RH Genotype Matched RBC Transfusions
Status
Recruiting
Phase
Phase 1/2
People taking part
35 people, planned
Started
30 Jan 2020
Expected to end
Oct 2029
Type of study
Interventional
Treatments tested
  • Red cell units that are genotype matched at the RHD and RHCE loci
Record updated
27 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with sickle cell disease who need regular red blood cell transfusions. It tests giving donor red cells paired to the patient's RH genotype.

Age
6 months and older.
Sex
All sexes can join.
Disease stage
Sickle cell disease of any genotype, needing a period of regular red cell transfusion treatment.

Main reasons for not taking part

  • A rare RH genotype that would make it hard to find enough red cell units
  • Antigen-negative blood needs due to alloimmunization that would make it hard to find enough units
  • Alloimmunization to the D antigen
  • Rh alloimmunization where RH genotype paired blood would go against standard of care and blood bank protocols
  • Parents/guardians or subjects who may not follow study schedules or procedures, in the investigator's opinion

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Subjects age >6 months
  • Diagnosis of SCD, all genotypes
  • Require a period of chronic red cell transfusion therapy
  • Subject/parental/guardian permission (informed consent) and if appropriate, child assent

Who cannot take part

  • Rare RH genotype that would preclude identification of sufficient RBC units
  • Antigen negative requirements due to alloimmunization that would preclude identification of sufficient RBC units
  • Alloimmunized to D antigen
  • Rh alloimmunized patients for whom providing RH genotype matched blood would expose the patient to an antigen that would not be consistent with standard of care and blood bank protocols
  • Parents/guardians or subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures

Where in United States

  • Children's Hospital of PhiladelphiaPhiladelphia, United StatesContact: Stella Chou, MDTaking people

About the trial

What the trial wants to find out

To determine the feasibility and efficacy of matching donor red cells by RH genotype for a cohort of chronically transfused patients with SCD.

The group in the trial

  • RH genotype matched red cell transfusionsTreatment being tested

    Subjects will receive RH genotyped matched red cell units for transfusion in addition to standard serologic C, E, and K antigen matching and being hemoglobin S negative, which is our institutional standard of care for patients with Sickle Cell Disease.

    Treatment: Red cell units that are genotype matched at the RHD and RHCE loci

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
RH Genotype Matched Red Cell Transfusions for Patients With Sickle Cell Disease
Plain-language title
Choosing donor blood by RH genes for sickle cell diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Publications
Record updated
27 April 2026